- Home
- AHG vs INBX Comparison
AHG vs INBX Comparison
Compare AHG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | INBX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.5M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AHG | INBX |
|---|---|---|
| Price | $1.33 | $79.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 242.1K |
| Earning Date | 12-15-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,777,798.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 512.09 | N/A |
| 52 Week Low | $0.83 | $10.81 |
| 52 Week High | $2.35 | $94.57 |
Technical Indicators
Market Signals| Indicator | AHG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 48.06 |
| Support Level | $1.24 | $76.22 |
| Resistance Level | $1.39 | $94.57 |
| Average True Range (ATR) | 0.12 | 6.98 |
| MACD | 0.02 | -1.37 |
| Stochastic Oscillator | 41.38 | 21.45 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.